Chugai Pharmaceutical (OTCMKTS:CHGCY) Shares Gap Down – Time to Sell?

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY)’s share price gapped down prior to trading on Tuesday . The stock had previously closed at $28.59, but opened at $27.21. Chugai Pharmaceutical shares last traded at $28.1910, with a volume of 28,978 shares traded.

Wall Street Analyst Weigh In

Separately, UBS Group raised shares of Chugai Pharmaceutical to a “strong-buy” rating in a report on Tuesday, January 27th. One investment analyst has rated the stock with a Strong Buy rating, According to MarketBeat, the stock has an average rating of “Strong Buy”.

Chugai Pharmaceutical Trading Down 3.4%

The stock has a market cap of $90.90 billion, a PE ratio of 31.75 and a beta of 0.63. The firm has a fifty day simple moving average of $26.84 and a two-hundred day simple moving average of $24.51.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last posted its quarterly earnings data on Thursday, January 29th. The company reported $0.25 earnings per share for the quarter. Chugai Pharmaceutical had a net margin of 34.47% and a return on equity of 22.22%. The company had revenue of $2.25 billion for the quarter. Equities analysts forecast that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.74 earnings per share for the current year.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.